Does Orlistat Reduce Appetite? How It Works

Orlistat is a widely used weight management medicine, but does orlistat reduce appetite? The short answer is no: orlistat works by blocking the absorption of dietary fat in the gut, not by suppressing hunger signals in the brain. Unlike GLP-1 receptor agonists such as semaglutide or tirzepatide, it has no direct effect on appetite or satiety hormones. Some people do eat less while taking it, but this is a behavioural response to avoiding uncomfortable side effects rather than a pharmacological one. Understanding how orlistat works helps set realistic expectations and supports informed decisions about weight management.

Does orlistat actually reduce appetite or just block fat?

Orlistat does not reduce appetite pharmacologically; it blocks fat absorption in the gut and has no effect on hunger or satiety pathways in the brain. Any reduction in eating is a behavioural response to avoiding gastrointestinal side effects.

Orlistat does not reduce appetite in the way that centrally acting medicines do; its primary action is to block the absorption of dietary fat rather than to suppress hunger signals in the brain.^[1][4] This is an important distinction for anyone considering it as a weight management option. Unlike GLP-1 receptor agonists such as semaglutide or tirzepatide, which act on appetite-regulating pathways in the central nervous system, orlistat works entirely within the gastrointestinal tract and has no direct effect on hunger or satiety hormones. For context on UK licensing: semaglutide is available as Wegovy (licensed for weight management) and Ozempic (licensed for type 2 diabetes); tirzepatide is available as Mounjaro, which is licensed for both type 2 diabetes and chronic weight management.^[16][17]

That said, some people do report eating less while taking orlistat, but this is generally considered a behavioural response rather than a pharmacological one. Because high-fat meals cause uncomfortable gastrointestinal side effects (described in more detail below), many people naturally reduce their fat intake, which can indirectly lead to lower overall calorie consumption. This behavioural adaptation may contribute to weight loss alongside the direct fat-blocking effect.

Orlistat is therefore best understood as a fat absorption inhibitor rather than an appetite suppressant. It is most effective when used alongside a reduced-calorie, lower-fat diet and increased physical activity. People hoping for a reduction in hunger or cravings may find that other licensed treatments are better suited to their needs, and a consultation with a healthcare professional can help identify the most appropriate option. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of clinically appropriate options may be considered.

What side effects should I watch out for when taking orlistat?

The most common side effects are gastrointestinal, including oily stools, increased bowel movements and flatulence, and are worse after high-fat meals. Rare but serious risks include liver injury and pancreatitis, requiring urgent medical attention.

The most common side effects of orlistat are gastrointestinal and are directly related to its mechanism of action: because unabsorbed fat passes through the gut, people frequently experience oily or fatty stools, increased frequency of bowel movements, flatulence with oily discharge, and, in some cases, faecal urgency or incontinence. These effects are more pronounced after meals that are high in fat, which is why dietary adherence is central to tolerating the medicine comfortably.

These gastrointestinal effects are generally mild to moderate and tend to improve over time as people adjust their diet. Keeping fat intake to no more than approximately 30% of total daily calories, spread evenly across meals, is the most effective way to minimise them, in line with the advice in the patient information leaflet for orlistat.

Serious but rare adverse effects have been reported in association with orlistat use, including severe liver injury and pancreatitis (including cases with severe outcomes).^[1][6] If you develop sudden severe upper abdominal pain (with or without vomiting), yellowing of the skin or eyes (jaundice), dark urine, or pale stools, stop taking orlistat and seek urgent medical attention. These symptoms may indicate pancreatitis or serious liver injury and should not be ignored.

Orlistat can also reduce the absorption of fat-soluble vitamins (A, D, E and K), so a daily multivitamin taken at least two hours before or after the orlistat dose is generally recommended.^[1][6]

Several important medicine interactions should be noted. People taking warfarin should have their INR monitored more closely when starting or stopping orlistat, as reduced vitamin K absorption may affect anticoagulant control.^[1][6] Levothyroxine should be taken at least four hours apart from orlistat, and thyroid function (TSH) should be monitored.^[1][6] Co-administration with ciclosporin is not recommended; if unavoidable, ciclosporin levels should be monitored closely. Orlistat may also reduce the effectiveness of some antiepileptics, antiretrovirals and amiodarone, and clinical response or drug levels should be monitored as appropriate if these medicines are used together.

Orlistat may increase urinary oxalate excretion, which can rarely lead to oxalate nephropathy. People with chronic kidney disease should discuss this risk with their prescriber before starting treatment, and anyone who develops flank pain or blood in the urine should seek medical assessment. Maintaining adequate hydration is advisable.

Suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. If you experience signs of a severe allergic reaction, such as difficulty breathing or significant facial swelling, call 999 immediately.

Who is orlistat suitable for, and how do I get it in the UK?

Orlistat is suitable for adults with a BMI of 30 kg/m² or above, or 28 kg/m² or above with a weight-related condition, and is available on prescription or over the counter as Alli 60 mg. NHS availability varies by Integrated Care Board area.

Orlistat is suitable for adults with a body mass index (BMI) of 30 kg/m² or above, or for those with a BMI of 28 kg/m² or above who also have a weight-related condition such as type 2 diabetes, hypertension or raised cholesterol.^[2][3] NICE guidance recommends that orlistat is prescribed as part of an overall weight management plan that includes dietary advice, physical activity support and behavioural change strategies.^[2][3] It is not recommended for use during pregnancy or breastfeeding.

Orlistat is indicated for adults only. The over-the-counter version (Alli 60 mg) is for adults aged 18 and over; prescription-strength orlistat 120 mg is not indicated for children.

In the UK, orlistat is available in two ways. Prescription-strength orlistat (120 mg capsules) is taken three times daily with each main meal containing fat, or up to one hour after the meal.^[1][6] If a meal is missed, or if a meal contains no fat, the dose should be omitted. This formulation is available on the NHS or privately via a GP or registered online pharmacy. A lower-dose, over-the-counter version (60 mg capsules, sold as Alli) is available from pharmacies without a prescription for adults aged 18 and over with a BMI of 28 kg/m² or above, following a consultation with the pharmacist.^[4][9] The same dosing timing applies: take with or up to one hour after each fat-containing main meal, and omit the dose if no meal is taken or the meal contains no fat. NHS prescribing is subject to local Integrated Care Board (ICB) commissioning decisions, so availability on the NHS may vary by area.

Orlistat is not appropriate for everyone. It should not be used by people with chronic malabsorption syndrome or cholestasis. For interaction management, see the side effects section above: warfarin users require INR monitoring; levothyroxine should be separated by at least four hours with TSH monitoring; ciclosporin co-administration is not recommended. A prescriber will review your full medical history and current medicines before recommending orlistat.

Continued prescribing is typically reviewed at three months: if you have not lost at least 5% of your initial body weight by that point, treatment is usually reconsidered. (A lower threshold of 3% may apply in some clinical contexts, such as type 2 diabetes; your prescriber will advise based on current NICE guidance and the BNF.)

If you experience severe diarrhoea while taking orlistat and use oral contraceptives, use additional contraceptive precautions during the episode, as absorption of the oral contraceptive may be reduced. Routine additional contraception is not specifically required with orlistat in the absence of severe diarrhoea.

How orlistat works in the body

Orlistat inhibits gastric and pancreatic lipases in the gut, blocking absorption of approximately one third of dietary fat, which is then excreted in the stool. It is minimally absorbed systemically and has no effect on the brain, appetite or metabolism.

Orlistat works by inhibiting gastric and pancreatic lipases, the enzymes responsible for breaking down dietary triglycerides into smaller fatty acids and monoglycerides that can be absorbed through the gut wall. By blocking these enzymes, orlistat prevents approximately one third of the fat consumed in a meal from being absorbed, meaning that fat passes through the intestine and is excreted in the stool rather than entering the bloodstream and being stored. This figure is supported by the EMA's assessment of orlistat and is reflected in the BNF monograph.

This mechanism is entirely local to the gastrointestinal tract. Orlistat is minimally absorbed into the systemic circulation, which means it does not affect the brain, heart or other organs directly. This local action distinguishes orlistat from some older weight management medicines that acted centrally. However, it also means that orlistat has no effect on appetite, metabolism or energy expenditure beyond the calories lost through unabsorbed fat.

The clinical benefit of orlistat depends heavily on dietary fat intake. If very little fat is consumed, very little fat is blocked, and the weight loss effect is correspondingly modest. Conversely, eating a high-fat meal while taking orlistat significantly increases the likelihood and severity of gastrointestinal side effects. This creates a built-in incentive to follow a lower-fat diet, which itself contributes to a calorie deficit. Clinical evidence, including data reviewed by the EMA and summarised in Cochrane analyses, indicates that orlistat used alongside dietary and lifestyle changes produces greater weight loss than lifestyle changes alone, though the magnitude of benefit varies between individuals.^[5][8] Regular follow-up with a healthcare professional helps to ensure the medicine continues to be appropriate and effective over time.

Scientific References

1. Xenical® 120mg PIL.
2. Overweight and obesity management (NG246): Prescribing orlistat, liraglutide and semaglutide.
3. Overweight and obesity management (NG246): Medicine options for weight management in adults.
4. Orlistat: a medicine to treat obesity.
5. Xenical EPAR – Scientific Discussion.
6. Xenical EPAR – Product Information (SmPC).
7. Xenical – EPAR summary page.
8. Assessment report for orlistat-containing medicinal products (Article 31 referral).
9. Orlistat monograph – BNF/NICE.
10. Orlistat interactions – BNF/NICE.
11. Levothyroxine interactions – BNF/NICE.
12. Warfarin interactions – BNF/NICE.
13. Orlistat safety update.
14. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
15. Tirzepatide monograph – BNF/NICE.
16. MHRA approves GLP-1 receptor agonist semaglutide (Wegovy) – new indication.
17. Semaglutide monograph – BNF/NICE.
18. MacWalter RS et al. Orlistat enhances warfarin effect. Lancet. 2003..
19. Yiu AJ et al. Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease. BMJ Case Reports. 2017..
20. Oxalate crystal-related acute renal injury caused by orlistat: A case report. Journal of Central South University Medical Sciences. 2022..
21. Overview of comments received on guideline on clinical evaluation of medicinal products used in weight control (revision 1).

Frequently Asked Questions